Clinical Trial Update: Efficacy and Safety Phase IIa Study of Myelo001 in Chemotherapy-Induced Neutropenia [Phase 2]

View source ↗

Summary

Phase IIa trial results assess the efficacy and safety of Myelo001 for chemotherapy-induced neutropenia with completed status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Chemotherapy-induced Neutropenia
• Myelosuppression

Drugs mentioned

• Myelo001 (Myelo001)

Snippet

Sponsor: Myelo Therapeutics GmbH | Conditions: Chemotherapy-Induced Neutropenia, Myelosuppression | Phase 2 | Status: COMPLETED